ALS Limited (ASX:ALQ)
Australia · Delayed Price · Currency is AUD | Market Cap | 11.97B +39.4% |
| Revenue (ttm) | 3.32B +10.7% |
| Net Income | 318.70M +24.4% |
| EPS | 0.63 +20.0% |
| Shares Out | 507.54M |
| PE Ratio | 37.44 |
| Forward PE | 26.34 |
| Dividend | 0.43 (1.80%) |
| Ex-Dividend Date | Jun 12, 2026 |
| Volume | 2,545,120 |
| Open | 23.36 |
| Previous Close | 23.43 |
| Day's Range | 23.36 - 24.05 |
| 52-Week Range | 15.97 - 26.17 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 23.95 (+1.53%) |
| Earnings Date | May 18, 2026 |
About ALS Limited
ALS Limited engages in the provision of professional technical services and analytical services primarily in the areas of testing, measurement, and inspection in Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States. It operates in two segments: Commodities and Life Sciences. The Commodities segment offers assaying and analytical testing, and metallurgical services for mining and mineral exploration companies. Its testing and consulting services cover the resource life cycle, including exploration, feasibility, opti... [Read more]
Financial Performance
In fiscal year 2026, ALS Limited's revenue was 3.32 billion, an increase of 10.69% compared to the previous year's 3.00 billion. Earnings were 318.70 million, an increase of 24.40%.
Financial StatementsNews
ALS Limited Earnings Call Transcript: H2 2026
Record FY 2026 results with revenue up 10.7% and NPAT up 25.8%, achieving FY 2027 targets a year early. Strong organic growth in Commodities and Life Sciences, robust cash generation, and disciplined capital allocation support continued investment and margin expansion into FY 2027.
ALS Limited Annual report: H2 2026
ALS Limited has published its H2 2026 annual report on May 17, 2026.
ALS Limited Slides: H2 2026
ALS Limited has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 17, 2026.
ALS Limited Earnings release: H2 2026
ALS Limited released its H2 2026 earnings on May 17, 2026, summarizing the period's financial results.
ALS Limited Earnings Call Transcript: H1 2026
Revenue rose 13.3% to AUD 1.7 billion with strong organic growth and margin improvement. Upgraded FY 2026 guidance targets 6%-8% organic growth, with commodities and life sciences both contributing, and robust cash generation supporting investments and dividends.
ALS Limited Quarterly report: H1 2026
ALS Limited has published its H1 2026 quarterly earnings report on November 17, 2025.
ALS Limited Slides: H1 2026
ALS Limited has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 17, 2025.
ALS Limited Earnings release: H1 2026
ALS Limited released its H1 2026 earnings on November 17, 2025, summarizing the period's financial results.
ALS Limited Transcript: Investor Day 2025
A refreshed strategy focuses on disciplined capital allocation, digital transformation, and targeted growth in minerals and environmental sectors. AI and automation are driving efficiency and margin gains, while a strong M&A pipeline and sustainability commitments support long-term value creation.
ALS Limited Slides: FY 2025
ALS Limited has posted slides in relation to its FY 2025 quarterly earnings report, which was published on July 31, 2025.
ALS Limited Transcript: AGM 2025
Solid FY2025 results with 16% revenue growth, strategic investments in lab upgrades, and a strong focus on digital transformation and sustainability. Board transitions and remuneration practices were discussed, with shareholders engaging on governance, growth, and technology risks.